Figure 5.

LIN01189 suppressed breast cancer progression

(A) Relative expression of LINC01189 in stable LINC01189-expressing MDA-MB-231 cells compared with the control cells determined by qRT-PCR. (B and C) MTT (B) and colony-formation (C) analyses of the proliferation of cells described in (A). (D) Transwell analysis of the invasion of cells described in (A). (E) wound-healing analysis of the migration of cells described in (A). (F) Tumor growth curves for subcutaneous tumor made of LINC01189-expressing MDA-MB-231 or control cells at the indicated times, and dissected tumors photographed at the time of harvest. (G) Bioluminescent imaging and quantification plot of mice harboring lung metastases after tail vein injection of LINC01189-expressing MDA-MB-231 or control cells. (H) Kaplan-Meier analysis of the recurrence-free survival of patients with different LINC01189 expression levels. (I) Morphology of cells as in (A). (J) Western blot was used to detect the expression of epithelial marker E-cadherin and mesenchymal marker vimentin in the cells described in (A). (K) The expression levels of epithelial marker E-cadherin and mesenchymal marker vimentin in the cells as in (A) were detected by immunofluorescence. (L) Immunohistochemical staining was performed to detect the expression of epithelial marker E-cadherin and mesenchymal marker vimentin in LINC01189-expressing MDA-MB-231 and control subcutaneous tumors. ∗p < 0.05.